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On the verge of entering the post-antibiotic era, numerous efforts are in place to regain 
the losing potential of antibiotics which are proving ineffective against common 
bacterial infections. Engineered nanomaterials, especially gold nanoparticles (GNPs) 
capped with antibacterial agents are proving to be an effective and novel strategy against 
multi-drug resistant (MDR) bacteria. In this study, we report a one-step synthesis of 
kanamycin-capped GNPs (20 ± 5 nm) utilizing the combined reducing and capping 
ability of the aminoglycoside antibiotic, kanamycin. Antibacterial assays showed dose-
dependent broad spectrum activity of Kan-GNPs against Gram-positive (Staphylococcus 
epidermidis and Enterococcus durans), Gram-negative (Escherichia coli and 
Enterobacter aerogenes) and Kan-resistant and MDR bacterial strains. A significant 
reduction in the minimum inhibitory concentration (MIC) of Kan-GNPs was observed as 
compared to free kanamycin against all the sensitive and resistant bacterial strains 
tested. Mechanistic studies using TEM and fluorescence microscopy showed that Kan-
GNPs exerted their bactericidal action through disrupting the cellular membrane 
resulting in leakage of cytoplasmic content and death of bacterial cells. Results of this 
study provide a novel method in the development of antibiotic capped GNPs as potent 




Bacteria belong to microorganisms which are part of earliest form of life existing 
on earth. There was a time when we humans were unaware of existance of tiny 
microorganisms. However, due to advancement in the field of microscopic and 
instrumental techniques we were able to provide proof that these tiny micrometer size 
organisms do exists and they are the causative agents for variety of diseases which were 
the ultimate cause of death in primitive days. Furthermore, researchers came up with 
more details regarding types of bacteria, their size and shapes, how they multiply and 
what their role is in life. It has been reported that there are at least 6 billion bacteria’s 
that reside on human body, but not all are pathogenic.1 With time, scientists started 
understanding how bacteria cause disease in a more sophisticated way and regarded 
pathogenic bacteria as “invisible enemies”.2 
The first antibiotic: penicillin was discovered in 19283 by Sir Alexander Fleming 
while he was studying and sorting culture of staphylococcus bacteria. During his 
research, he found an unexpected growth of colonies in one of his petri plates which he 
further identified as growth of mold of strain Penicillium notatum. He later had an idea 
that this mold is responsible for secretion of some unknown substance which inhibited 
the growth of bacteria. By the splendid discovery of antibiotic, every individual gained a 
ray of hope that “Yes! now we can treat bacterial infections and live longer!” With 
increase in other common infections and subsequent discovery of new generations of 
available antibiotics or new classes of antibiotics, the faith in modern medicine persisted 
and people enjoyed novelty of medicine. Hence, antibiotics were more commonly called 




Since the serendipitous discovery of the penicillin3, the process of developing 
resistance against antibiotics had been initiated in bacteria which was clearly evident 
from the presence of resistant bacterial strains in the early 1930's and 1940's.5,6 The 
reason behind bacterial resistance to the effect of antibiotic is attributed to mechanisms 
acquired or developed by bacteria such as “inactivation of drug by enzymes, alteration 
of drug target, activation of drug efflux pump and inhibition of drug uptake” etc.7 These 
resistant bacterial genes transfer from one generation to other and spread globally. 
Antibiotic resistance was also exaggerated by other contributing factors such as 
widespread use of antibiotics for livestock production, over the counter use for human 
consumption, improper diagnosis, leading to prescription of antibiotics in viral 
infections and dry new antibiotic pipeline, etc.5–8 
The bacterial resistance has increased from single infection to range of infections 
caused by bacteria, resulting in emergence of multi-drug resistant (MDR) bacterial 
strains more prevalently known as "superbugs".8–13 Common examples of such 
infections includes methicillin-resistant Staphylococcus aureus (MRSA), carbapenam-
resistant enterobacteriaceae (CRE), extended spectrum β-lactamase producing 
enterobacteriaceae (ESBLs), etc.14,15 Most of these infections are hospital acquired 
infections.16 According to World Health Organization (WHO), out of every 100 in-
patients, at least 7 patients in high-income and at least 10 patients in low-/middle income 
countries may acquire a hospital acquired infection.17 The rate at which bacteria are 
becoming resistant to existing antibiotics is faster than the development of novel 




such as organ transplantation, and common surgeries which are at higher risks of post-
operative infections.14,18,19 
According to the recent report by Centers for Disease Control and Prevention 
(CDC), more than 23,000 people die annually from resistant bacterial infections in the 
United States.15 Hence, dominance of antibiotics are superseded by bacteria and we are 
failing to treat common bacterial infections. This current situation can be summed up in 
a single phrase where we are able to counteract big wars, but we are losing war to these 
tiny bugs.4 Therefore, it requires an urgent call to curb ill effects of MDR bacteria and 
prevent it from becoming pan-drug resistant (PDR) bacteria i.e., bacteria becoming 
resistant to all available antibiotics.14,15 
Several strategies are being employed to develop novel antibacterial agents. 
Aware of the exorbitant cost and time required to conduct research, scale up production, 
validate a process, and get an approval from regulatory bodies leading to success in a 
new chemical entity into the market, the current focus is shifting from developing new 
antibiotics to potentiating the activity of commercially successful antibiotics using 
alternative methods.20 Nanotechnology is one of the alternative route which is been 
under study for biological applications. It involves nanoparticles which deals with 
particles in size range of one billionth of a meter (1-100 nm).21 Nanoparticles possess 
unique optical properties when compared to bulk particles.21,22 They have been studied 
for various applications such as diagnosis,23 biosensors,24 catalysis,25 
photothermolysis,26 drug delivery27 and gene therapy (Figure 1).28 Various researchers 




pharmacological activity compared to bulk drug. For example, Gu et al have reported 
multiple fold in vivo potency for vancomycin-GNPs against vancomycin resistant 
enterobacteriaceae.29 Abraxane® (paclitaxel-albumin stabilized nanoparticle 
formulation) has been approved by USFDA in September 2013.30 Till date, no safety 






























Figure 1. Illustrates applications of gold nanoparticles. Gold nanoparticles are being 
studied for variety of applications such as diagnosis, biosensors, catalysis, 




One of the widely researched strategies involves use of metallic and metal oxide 
nanoparticles (1-100 nm) such as gold (Au), silver (Ag), zinc oxide (ZnO) and many 
more for their synergistic role in enhanced bactericidal activity.32,33 Among various 
inorganic nanomaterials, gold nanoparticles (GNPs) have gained immense attention in 
designing and developing new biomedical applications.21,22,34 Recently, ultra-fine, non-
toxic GNPs are also being widely studied for combating endemic MDR bacteria.29,33,34 
Some of the inherent features of GNPs such as biosafety,35,36 ease of functionalization,37 
facile synthesis,22,38,39 and large surface/volume ratio allowing the release of high drug 
payload at the infected sites.40 GNPs also provides multiple-targets of bactericidal 
action, ability to penetrate biological membranes20,40 and many other relevant features 
that make GNPs the preferred candidates for developing novel antibacterial agents. 
Unlike the wide use of nanoparticles for cancer therapy,41–43 less extensive efforts have 
been made in the field of antibacterial agents as evident from a lack of FDA approved 
antibacterial formulation based on nanotechnology.33 Common methods that are 
employed for making GNPs involve multi-stepped use of organic chemicals and harsh 
reaction conditions, which could have detrimental effects on biological systems.44–49 
As an alternative route to prepare novel antibacterial nanoformulation by capping 
antibiotic onto GNPs in biofriendly manner, we selected kanamycin antibiotic. 
Kanamycin sulfate, derived from Streptomyces kanamyceticus, is a broad spectrum 
aminoglycoside antibiotic discovered in 1956.50 Kanamycin is also classified under 
essential medicine list by WHO.51 Kanamycin is used in treatment of infections caused 




Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, and 
Acinetobacter species.52–54 These organisms belong to a class of “ESKAPE” organisms 
which are primary cause for hospital acquired infections in U.S.55 Kanamycin acts by 
binding onto the 30S ribosomal subunit in prokaryotes thereby inhibiting protein 
synthesis.52,56 Bacteria have developed resistance to the antibacterial effects of 
kanamycin, thereby limiting its use in therapy.52 
We took an approach to develop antibiotic capped gold nanoparticles for potent 
antibacterial activity to curb the ill effects of resistant bacteria. Extending the scope of a 
method57,58 we developed to efficiently generate biomolecules capped-GNPs, in this 
study we report a simple kanamycin-mediated, bio-friendly synthesis and concomitant 
capping of GNPs, resulting in enhanced broad-spectrum antibacterial activity. 
In this study, we synthesized Kan-GNPs and optimized its synthesis process. The 
synthesized Kan-GNPs were morphologically characterized using transmission electron 
microscopy (TEM), scanning electron microscopy, energy dispersive spectroscopy, UV-
Vis spectroscopy, thermo gravimetric analysis, zeta potential and dynamic light 
scattering. Furthermore, Kan-GNPs were evaluated for their antibacterial efficiency 
against Gram positive, Gram negative, kanamycin sensitive, kanamycin resistant and 
multi-drug resistant (MDR) bacterial strains. Using TEM, we visualized morphological 
changes occurring in bacteria upon treating with minimum inhibitory concentration 
(MIC) concentration of Kan-GNPs. Our results demonstrate the successful development 
of a highly efficient Kan-GNPs against several infectious bacterial strains, suggesting a 











Formvar 15/95 resin, powder 63450-15-7 Electron Microscopy Sciences 
Glycerol GX0190-6 EMD Chemicals 
Kanamycin sulfate 80058-286 Calbiochem 
L.B agar media 240110 BD Company 
L.B media 71753-6 Novagen 
Menadione ME105 Spectrum Chemicals 
Potassium aurochlorate 450235 Sigma Aldrich 
Potassium phosphate, dibasic (K2HPO4) PX1570-1 EMD Chemicals 
Potassium phosphate, monobasic 
(KH2PO4) 
PX1565-5 EMD Chemicals 
Potassium sulphate PX1595-1 EMD Chemicals 
Propidium iodide 537059 Calbiochem 
Sodium chloride 3624-05 J.T. Baker 
Sodium phosphate, dibasic, 12-Hydrate SX0718-1 EMD Chemicals 
T.S agar media 236950 BD Company 
T.S media T0420 Teknova 
XTT salt 10060 Biotium 
Table 1. Represents list of all the chemicals used for the research project with catalog 















96 well Flat Bottom, Non-Treated, Sterile, 
Polystyrene, Microtiter Plates 
25381-056 Costar 
Microcentrifuge Tubes – 1.5 mL 87003-294 VWR 
Falcon Tubes – 15 mL 89039-666 VWR 
Falcon Tubes – 50 mL 89004-364 VWR 
Glass Culture tubes  14-961-27 Fisher brand 
Micropipette Tips (1-20 µL) 53509-070 VWR 
Micropipette Tips (1-200 µL) 53503-606 VWR 
Micropipette Tips (1-1000 µL) 83007-382 VWR 
Nalgene™ Oakridge High speed PPCO 
centrifuge tubes 
3119-0030 Thermo Scientific 
Sterile Polystyrene Petri Dish 
(100 mm x 15mm) 
875713 Fisher Scientific 
TEM grids 




















Equipment’s  Use   
Autoclave Machine, GETINGE Sterilize solutions and supplies 
Centrific centrifuge (Model 228) 
Concentrate gold nanoparticles 
(Medium scale) 
Eppendorf Centrifuge 
Concentrate gold nanoparticles 
(Small scale) 
Excella E25 Incubator Shaker Bacterial and nanoparticle incubation 
-80 °C Freezer, Thermo scientific Store bacterial stock culture 
Hitachi U-3900 Spectrophotometer 
Optical absorption of nanoparticle 
solution 
JEOL JEM-1400 Plus Electron Microscope 
Morphological characterization of 
kanamycin gold nanoparticles 
JEOL JSM-5400 LV Scanning Microscope 
Elemental composition of 
nanoparticles 
Thermo scientific Bath Circulator (Haake A25, 
Haake SC150) 
Temperature dependent synthesis of 
nanoparticles 
LABONCO Biological Safety Cabinet, Logic, 
Class II, Type A2 
Working with bacteria 
(aseptic conditions) 
LABONCO Centrivap Cold Trap Lyophlizer Freeze-drying of gold nanoparticles 
METTLER TOLEDO New Classic MF Balance 
(Model: ML 54/03) 
Weighing of raw materials, 
nanoparticles etc. 
MISONIX ultrasonic Liquid Processor XL-2000 
Probe Sonicator (Model: CML-4) 
Break the aggregation of 
nanoparticles 
NANOpure infinity, Ultrapure water system, 
Barnstead water machine  
Nano pure water (17.8-18.3 mΩ-cm) 
Petri Plate Scanner Counting colonies on petri plates 
Refrigerator Storing the solutions and reagents 
SPECTRONIC 20D+ Thermo Spectronic To check optical density of bacteria 
Sorval RC-5B/5C Plus centrifuge 
Concentrate gold nanoparticles 
(Large scale synthesis) 
Synergy H1 Hybrid Plate reader, Biotek Bacterial growth assay 
TA Thermogravimetric Analysis, Q5000 
Organic percent determination on 
gold nanoparticles 
VWR Incubator   Growth of bacteria on agar plates 
Zetasizer Nano S (Malvern Instruments Ltd.) Particle size distribution 








2.4. Bacterial strains used for investigation 








Escherichia coli 67877 
Yersinia pestis CO92 
Kanamycin resistant bacteria 
__ 
Yersinia pestis CO92::Km 
Pseudomonas aeruginosa PA01 
Multi-drug resistant bacteria 
Pseudomonas aeruginosa UNC-D-1 
Table 4. List of Gram positive, Gram negative, kanamycin resistant and multidrug 
















2.5. Preparation of reagents 
2.5.1. Cleaning protocol 
All the glassware/apparatus/containers were thoroughly rinsed and washed with 
soap water followed by tap water and nanopure water and allowed to air dry. 
Furthermore, the apparatus were subjected to dry heat sterilization before use. 
2.5.2. Preparation of sterile nanopure water 
500 mL of nanopure water was collected in a sterile 1000 mL glass bottle. The cap 
was screwed loosely and the nanopure water was sterilized by moist heat sterilization 
using an autoclave. 
2.5.3. Preparation of minimal media [M9 media without NH4Cl] (1L, pH 7.2 ± 0.2) 
Following cleaning protocol, a 1 L Erlenmeyer flask, two 1 L glass bottles, a 1 L 
graduated cylinder, a magnetic stirrer and a spatula was obtained. 13 g potassium 
phosphate, monobasic (KH2PO4), 10 g potassium phosphate, dibasic (K2HPO4), 9 g 
sodium phosphate, dibasic, 12-Hydrate (Na2HPO4), and 2.4 g potassium sulphate 
(K2SO4) were weighed accurately and transfered it to the 1 L Erlenmeyer flask. 
Approximately 800 mL of nanopure water was added to the Erlenmeyer flask. The 
contents of the Erlenmeyer flask were mixed to dissolve completely using a magnetic 
stirrer. In a large graduated cylinder, the volume was made up to 1000 mL using 
autoclaved nano pure water. 500 mL of solution was transferred to each 1 liter glass 
bottles. The bottles cap were screwed loosely and were sterilized by moist heat 




2.5.4. Preparation of kanamycin sulfate stock solution: (1.72 mM, 30 mL) 
𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑘𝑎𝑛𝑎𝑚𝑦𝑐𝑖𝑛 (𝑔)









30 mg of kanamycin sulfate (see Appendix A for product specification) was 
weighed using microbalance and transferred to 50 mL falcon tube. 30 mL of M9 media 
(without NH4Cl) was added to the falcon tube. The falcon tube was thoroughly vortexed 
in order to mix and dissolve the drug and a clear solution was obtained. 5 mL of drug 
solution was then transferred to six different 15 mL falcon tubes. 
2.5.5. Preparation of potassium gold (III) chloride stock solution (KAuCl4) (0.79 
mM, 5.0 mL) 
𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑔𝑜𝑙𝑑 𝑠𝑎𝑙𝑡 (𝑔)









250 mg of gold salt was weighed and transferred to 15 mL Falcon tube. 5 mL of 
sterile nanopure water was added to it. The mixture was vortexed to dissolve solute until 
clear, homogenous yellow solution was obtained. The falcon tube was covered with 
aluminum foil to protect from light. The tube was further stored at 2-8 °C in a 
refrigerator until further use. 
2.5.6. Preparation of Luria-Bertani media (LB) (1L) 
Following the cleaning protocol, 25 g of L.B media was weighed accurately and 




water was added to it. The L.B media was completely mixed and dissolved in nanopure 
water using a magnetic stirrer. The volume was made up to 1000 mL using autoclaved 
nanopure water in a graduated cylinder. The resulting solution was then further 
transferred equally into two glass bottles (1 L capacity) and sterilized using autoclave. 
The solution was further stored in a refrigerator between 2-8 °C until further use. 
Note: It is highly recommended to prepare fresh stock every time before use. 
2.5.7. Preparation of Tryptic-Soy media (T.S) (1L) 
Following the cleaning protocol, 30 g of T.S media was weighed accurately and 
transferred to 2 L Erlenmeyer flask. Approximately 800 mL of autoclaved nanopure 
water was added to it. The T.S media was completely mixed and dissolved in nanopure 
water using magnetic stirrer. The volume was made up to 1000 mL with nanopure water 
using a graduated measuring cylinder. The resulting solution was then further transferred 
equally into two glass bottles (1L capacity) and sterilized using autoclave. The solution 
was further stored in a refrigerator at 2-8 °C until further use. 
2.5.8. Preparation of L.B/T.S agar plates 
Following the cleaning protocol, 40 g of L.B agar/T.S agar was weighed and 
transferred into a 2 L Erlenmeyer flask. Approximately 800 mL of autoclaved nanopure 
water was added to it. The agar media was completely mixed and dissolved in nanopure 
water using a magnetic stirrer. The volume was made up to 1000 mL in a graduated 
cylinder using autoclaved nanopure water. The flask was then covered with double 
folded aluminum foil and sterilized using moist heat sterilization. In the meantime, 




cabinet. After sterilization of agar media, the flask was allowed to sit for pproximately 5 
minutes. 25 mL of sterilized media was poured in each petri dish using 50 mL falcon 
tube. At room temperature, the plates were allowed to solidify in biological safety 
cabinet by covering half portion of cap open. After solidification, the plates were 
wrapped using parafilm around its circumference, labeled and stored in refrigerator 
between 2-8 °C for further use. Note: The solidification of agar takes place at 
approximately 35 °C. Hence, care should be taken after autoclave for not allowing flask 
to sit for longer time.  
2.5.9. Preparation of 10X phosphate buffer saline (PBS) (1L, pH 7.2 ± 0.2) 
Following the cleaning protocol, 5.519 g sodium dihydrogen phosphate, 42.89 g 
disodium hydrogen phosphate and 87.66 g sodium chloride were weighed and 
transferred it to 2 L Erlenmeyer flask. Approximately 800 mL of autoclaved nanopure 
water was added and the solutes were mixed to dissolve. The volume was made up to 
1000 mL in a graduated measuring cylinder using autoclaved nanopure water. The pH of 
solution was adjusted to pH 7.2 using calibrated pH meter. The 500 mL of solution was 
transferred to two reagent bottles, screw capped loosely and subjected to moist heat 
sterilization. After sterilization, the bottles were labeled, screw capped tightly and stored 
at room temperature until further use. 
2.5.10. Preparation of 1X phosphate buffer saline (PBS) (0.5L, pH 7.2 ± 0.2) 
Following the cleaning protocol, 50 mL of 10X PBS was diluted to 500 mL 
using autoclaved nanopure water in a graduated cylinder. The pH of solution was 




reagent bottle, screw capped loosely and subjected to moist heat sterilization. After 
sterilization, the bottles were labeled, screw capped tightly and stored at room 
temperature until further use. 
2.5.11. Preparation of tetrazolium salt solution (XTT) (30 mL) 
Following the cleaning protocol, 30 mg of XTT dye was weighed and transferred 
to 100 cc Erlenmeyer flask containing 30 mL of phosphate buffer saline (1X PBS, pH 
7.2). The flask was covered with double folded aluminum foil (protected from light) and 
sterilized using moist heat sterilization method. After sterilization, 995 µL of XTT 
solution was aliquot (under aseptic conditions) into 1.5 mL eppendorf centrifuge tubes, 
labelled and stored at -4 °C freezer until further use. 
2.5.12. Preparation of menadione solution (10 mM, 50 mL) 
𝑀𝑜𝑙𝑎𝑟𝑖𝑡𝑦 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑒𝑛𝑎𝑑𝑖𝑜𝑛𝑒 (𝑔)









Following cleaning protocol, 86 mg of menadione was weighed accurately and 
dissolved in 50 mL acetone in a 100 mL glass bottle. The bottle was labelled and stored 
in a refrigerator at -4 °C for further use. 
2.5.13. Preparation of 1 % formvar solution 
Prepare a 1 % solution of formvar by dissolving 1 gram polyvinyl formvar 
desiccated resin powder in 100 mL ethylene dichloride solvent. Keep the reaction 




2.5.14. Preparation of TEM grids 
A 400 square mesh, oval hole copper grids were obtained and washed in 1 M HCl 
solution in order to remove any dust particles followed by air drying. The grids were 
further washed in water and air dryed. A final wash with acetone followed by air drying 
was done for copper grids. The burette apparatus was set up and formvar coating 
solution was added into burette. A clean glass slide was dipped into the burette holding 
formvar solution and kept in contact for approximately 30 seconds. The glass slide was 
removed using tweezer and air dried. A surgical grade blade was used to scrap the edges 
of the glass slide. This process technically provides different films on each side of glass 
slide. The film coating was then further removed from glass slide by immersing it into a 
glass jar completely filled with distilled water. The formvar film so obtained was 
deposited onto light side of washed copper grids by holding copper grids inversely (light 
side facing downwards) and placing it onto formvar film at surface of water. Parafilm 
was used to obtain formvar film containing copper grids. The copper grids (with formvar 
film on top) were then removed from parafilm using sharp tweezer and kept separately 







2.6. Experimental Methods 
2.6.1. Synthesis of Kanamycin gold nanoparticles (Kan-GNPs) 
Kan-GNPs was synthesized in a single step process (Figure 2) which involves a 
reaction of kanamycin drug in an aqueous buffer with an aqueous solution of KAuCl4. 
Aiming at making monodisperse and stable Kan-GNPs with a uniform particle size, we 
carried out reactions at different concentrations of each reaction components. The 
combination which yielded desired morphology of Kan-GNPs with high percentage 
yield was selected. For a typical synthesis, 1.72 mM of kanamycin was dissolved in 
aqueous buffer (pH ~7.2 ± 0.2) and was preheated above room temperature. 
Furthermore, 0.79 mM of KAuCl4 (30 µL from 50 mg/mL solution) was added and 
reaction mixture was incubated for 5 minutes. After incubation, the reaction tubes were 
removed and cooled at room temperature. The formation of Kan-GNPs was confirmed 
by visual change of a reaction mixture from colorless to pink. The Kan-GNPs 
suspension was then subject to repeated washing with autoclaved nanopure water and 
centrifugation (15,000 rpm for 20 minutes) to remove any traces of free reactants 
remaining in the reaction mixture. Sterile oakridge tubes were used for centrifugation in 
Sorval RC 5B/5C Plus Centrifuge set with F21 rotor. Supernatant solution was discarded 
at each centrifugation step and replaced with autoclaved nanopure water for further 
washing. The concentrated Kan-GNPs suspension was then obtained after final washing 


























Figure 2. Illustrates a single step scheme for Kan-GNPs synthesis. In this process, 




2.6.2. Freeze-drying of synthesized Kan-GNPs 
Freeze-drying of Kan-GNPs had various advantages such as ease in storage, 
weighing and handling and convenience in determining the dose of Kan-GNPs to be 
selected for further antibacterial testing. This also indicates robustness of manufacturing 
process with respect to percentage yields. For freeze-drying process, Kan-GNPs (100 
mL batch) was synthesized, washed, centrifuged, and concentrated to a final volume of 2 
mL in nanopure water. The LABONCO Centrivap Cold Trap Lyophlizer was switched 
on 2 hours prior to freeze-drying to attain - 30 °C temperature. Concentrated Kan-GNPs 
suspension was then transferred to two different stainless steel cups, freezed in liquid 
nitrogen, and covered with miracloth which allowes loss of moisture but not permeable 
for loss of nanomaterials. The cups were then readily transferred to lyophilization 
chamber (previously cooled and maintained at -30 °C). The chamber was closed and 
vacuum was switched on. The samples specimen were kept overnight under freezing 
conditions. Temperature variation was performed the following day with increasing 
temperature by 5 °C at specific time interval. At 30 °C, the lyophlizer was switched off 
and the dried Kan-GNPs were collected, weighed accurately and stored in a glass vial at 
room temperature for further analysis. 
2.6.3. Characterization of Kan-GNPs 
Though synthesis of Kan-GNPs was physically noted by change in color of the 
reaction mixture, still it is very important to determine if kanamycin is actually capped 
onto gold nanoparticle surface. Thus, various electron microscopic and spectroscopic 




UV-Vis spectroscopy (UV-Vis)  
Gold nanoparticles possess a characteristic optical property, called surface 
plasmon resonance (SPR).59 This SPR band is observed in visible range of light and it 
depends on the size of particles, shape of particles and chemical environment in which 
nanoparticles (NPs) are present. Hence, UV-Vis spectroscopy was used as a qualitative 
analytical spectrometric technique to confirm the formation of Kan-GNPs. A dilute 
suspension of Kan-GNPs was probe sonicated for 30 seconds at 45 % amplitude. UV-
Vis absorption spectrum of resulting suspension was recorded in the wavelength range 
of 400-850 nm using a Hitachi U-3900 spectrophotometer at a resolution of 0.5 nm and 
scanning speed of 600 nm/min while maintaining slit width at set value of 5 nm and path 
length 10 mm. 
Dynamic light scattering (DLS) 
DLS is a rapid and accurate technique used to characterize nanoparticles 
suspended in liquid medium.60 Diameter and average particle size distribution of 
synthesized Kan-GNPs were determined using a Zetasizer Nano S (Malvern Instruments 
Ltd.). The motion of nanoparticles in suspension leads to scattering of laser light at 
different intensity, causing intensity fluctuations, which is further recorded and 
analyzed, and particle velocity was determined. To analyze Kan-GNPs, dilute 
suspension of Kan-GNPs was probe-sonicated for 30 seconds at 45 % amplitude. The 
average of three individual measurements in total of 13 runs was recorded in 1 mL of 
sample. The data so obtained was plotted and average particle size distribution along 




Transmission electron microscopy (TEM)  
Transmission electron microscope possesses high image resolution at nanometer 
range.58 It works based on the principle of interaction of beam of an electron with a thin 
specimen sample, thus transmitted electrons produce an image of sample on phosphorus 
screen and the size and shape of nanoparticles were determined. To analyze Kan-GNPs, 
a dilute suspension of Kan-GNPs was probe sonicated for 30 seconds at 45 % amplitude. 
10 µL of above suspension was loaded onto 400 square mesh, oval hole formvar coated 
copper grid and was allowed to air dry before observing under JEOL JEM-1400 Plus 
transmission electron microscope. The sample was allowed to be in contact with 
formvar film on grid. Excess sample was wiped off using filter paper wedge. The beam 
of an electron was maintained at 100 kv electron voltage and the image of desired region 
was taken at different magnifications using a built-in camera. The scale bar of the 
respective size of an image automatically was included in image based on magnification 
value.  
Scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS) 
Surface morphology of Kan-GNPs was studied using scanning electron 
microscopy (SEM) and elemental compositions including a gold and carbon was 
detected by high sensitive energy dispersive X-Ray spectroscopy (EDS) using a JEOL 
JSM-5400 LV with IXRF system. For a typical analysis, 50 µL of Kan-GNPs 
suspension (previously probe sonicated) was pipetted on rough side of clean silicon 
chip. The silicon chip containing sample was spin coated and placed in a petri plate and 




then imaged onto SEM and elemental composition was determined using EDS. The 
SEM images were then exported into a built-in software and elemental composition of 
Kan-GNPs was determined at different sampling spots using IXRF system. The presence 
of organic compound was confirmed onto GNPs surface and the elements and their 
respective percent weights were then detected. 
Thermogravimetric analysis (TGA) 
Thermal analysis is an important quantitative method to determine amount of 
organic content capped on GNPs surface.61 To determine how much kanamycin is 
coated on GNPs, 5-10 mg of freeze dried powder of Kan-GNPs was placed in a platinum 
pan which was supported by a highly precise balance. The pan was introduced into 
furnace chamber in Q5000 TGA and subjected to thermal decomposition from room 
temperature till 850 °C. The sample environment is governed by sample purge gas used. 
Two types of methods (i.e., using nitrogen and air as purge gas) were employed to study 
the thermal degradation of Kan-GNPs (Appendix B: Method). In method I, Kan-GNPs 
were thermally degraded in inert conditions using nitrogen as purge gas till 650 °C 
followed by air till 850 °C to facilitate complete degradation of the organic content. In 
method II, air was used as a purge gas right from room temperature to 850 °C to 
facilitate complete oxidation of kanamycin. The weight loss of Kan-GNPs was 
monitored as a function of temperature throughout the experiment. A thermogram with 
percent weight on Y-axis and temperature on X-axis was plotted using universal TA 




analysis experiment of Kan-GNPs was repeated three times to confirm the percent 
weight of kanamycin on GNPs surface. 
Zeta potential 
Zeta potential provides a net electrical charge at the interface in colloidal 
system.62 For nanoparticles suspension, measuring charge of GNPs is a very key 
parameter for predicting its stability. It is also reported that negatively charged bacterial 
cell membrane attracts positively charged nanoparticles, thereby contributing to the 
bactericidal action of GNPs. Kan-GNPs were analyzed for zeta potential using Zetasizer 
Nano S (Malvern Instruments Ltd.) equipment. Kan-GNPs showed positive charge of 
+23.4 mV. 
2.6.4. Evaluation of antibacterial activity of Kan-GNPs 
Kan-GNPs were tested for in vitro antibacterial activity against Gram-positive 
(Staphylococcus epidermidis and Enterococcus durans), Gram-negative (Escherichia 
coli and Enterobacter aerogenes), kanamycin resistant (Y. pestis C092::km) and multi-
drug resistance (P. aeruginosa UNC D-1) bacterial strains. 
Preparation of glycerol stock of bacterial strains 
A fresh glycerol stock of desired bacterial strains were prepared in respective 
nutrient media when required. A preculture of desired bacterial strain was grown by 
adding 200 µL of bacterial stock in 10 mL of respective nutrient media (L.B/T.S) in a 50 
mL UV sterilized falcon tube. The bacterial suspension was mixed and incubated 
overnight in a incubator shaker at 37 °C, 150 rpm for 12-20 hours. After incubation 




of bacterial culture at 600 nm using 4 mL of culture in a clean sterilized glass testube in 
Spectronic-20 spectrometer corrected with a blank. When the O.D of bacterial culture 
reached to a value of ~1.2, a 1.5 mL (10 %) of glycerol was added to the bacterial 
culture in falcon tube and mixed thoroughly. 250 µL of resulting suspension was aliquot 
into 1.5 mL sterilized labelled eppendorf centrifuge tubes. The culture containing tubes 
immediately kept in contact with liquid nitrogen and freezed. After all the tubes were 
completed for preparing an aliquot, the culture containing tubes were transferred to – 80 
°C freezer until further use. The entire process of preparing a glycerol stock was 
conducted in biological safety cabinet in the presence of blue flame using bunsen burner 
to ensure aseptic conditions. 
Preparation of preculture of bacterial strains 
A preculture of desired bacterial strain was prepared by thawing the glycerol 
stock of respective bacterial strain. 10 mL of nutrient media (L.B/T.S) was added into 50 
mL UV sterilized falcon tube. 200 µL of thawed bacterial suspension from glycerol 
stock was transferred into falcon tube. The sample was mixed properly and then 
incubated overnight at 37 °C, 150 rpm for ~12-20 hours. The growth of bacteria was 
determined by testing O.D of bacterial culture. The desired O.D for testing is ~1.2. 





















37 °C, 150 rpm, 
12-14 hrs 
Enterococcus durans T.S Broth 






37 °C, 150 rpm, 
12-14 hrs 
Escherichia coli L.B/T.S Broth 
37 °C, 150 rpm, 
12-14 hrs 
Table 5. Represents incubation time and conditions for preparing small scale preculture 
of various Gram positive and Gram negative bacterial strains tested. 
 
In-vitro antibacterial assay 
In-vitro antibacterial activity of Kan-GNPs were tested on the basis of dose 
against Gram-positive (Staphylococcus epidermidis and Enterococcus durans), and 
Gram-negative (Escherichia coli and Enterobacter aerogenes) bacteria at Dr. 
Rajalingam Dakshinamurthy`s lab. The effect of Kan-GNPs against kanamycin 
resistance bacteria (Y pestis CO92::km) and MDR bacteria (P. aeruginosa UNC D-1) 
were tested at the Dr. Matthew Lawrenz lab at the Center for Predictive Medicine, 
University of Louisville School of Medicine. For the control, the cognate antibiotic 
kanamycin (i.e., kanamycin without GNPs) was included in all studies. The minimum 
inhibitory concentration (MIC) was calculated from the average MIC of three individual 
experiments. The MIC values obtained were utilized to establish experimental 
conditions for testing kanamycin resistant and MDR bacterial strains. The concentration 




of 3x105 CFU per mL of bacterial suspension was used for antibacterial testing for 
kanamycin resistant and MDR bacterial strains. 
Bacterial growth curve assay  
The bacteriostatic/bactericidal activity elucidation of Kan-GNPs was performed 
to measure cell viability after exposure to Kan-GNPs nanoformulation as a function of 
time.58,63 The lowest concentration of Kan-GNPs required to kill bacterial cells was 
determined as MIC against the particular bacterial strain.64,65 The in vitro antibacterial 
assay was performed in a 96 well microtiter plate (Appendix D). The circumference of 
microtiter plate was filled with sterilized nanopure water to prevent loss of sample due 
to evaporation from sample wells during incubation conditions. Each reaction plate 
contained three sample rows (comprising of Kan-GNPs + nutrient media and bacterial 
cells) to study the effect of Kan-GNPs on growth of bacteria, one row as positive control 
(comprising nutrient media + bacterial cells) to study growth of bacteria in the absence 
of Kan-GNPs and one blank row as a negative control (comprising of Kan-GNPs + 
nutrient media) to subtract the absorbance for Kan-GNPs and nutrients by themselves. 
A standard stock solution of Kan-GNPs (1 mg/mL) was prepared using 
autoclaved nanopure water which was used to make various concentrations required for 
the antibacterial study. Growth of Gram-positive (Staphylococcus epidermidis and 
Enterococcus durans) and Gram-negative (Escherichia coli and Enterobacter 
aerogenes) bacterial strains in the presence of Kan-GNPs was measured using a 
microtiter broth method.64 Test samples contained serial dilutions of Kan-GNPs with a 




cultures of a bacterial strain grown overnight at 37 °C, 150 rpm were inoculated into the 
sample wells. A final volume of 250 µL was achieved in each well using the respective 
nutrient media. Wells containing the same concentration of Kan-GNPs (100 µL) with 
150 µL of growth media were used as a negative control. For the positive growth 
control, the same volume of Kan-GNPs was replaced with equal amount of nanopure 
water. The plates were incubated at 37 °C, 150 rpm. Using a microtiter plate reader, the 
optical density at 600 nm (OD600 nm) was measured every three hours for a period of 12 
hours. A graph of O.D 600 nm was plotted against time (hrs). The same procedure was 
repeated for pure kanamycin and MIC values were compared with that of Kan-GNPs. 
Spread Plate Assay 
In addition to the growth curve assay, solid agar plate assay was performed to 
check the viable bacterial cells in the presence of different concentrations of Kan-
GNPs.58,63 Spread plate assay was used to determine minimum bactericidal 
concentrations (MBC) i.e., the lowest concentration of Kan-GNPs that kills 99.9 % of 
bacteria upon treating with nanoparticles. 
For this study, a respective bacterial strain was incubated in the presence and 
absence (control) of Kan-GNPs for 12 hours at 37 °C and 150 rpm. Following the 
incubation time, small volume of bacterial suspension samples were evenly spread onto 
a fresh, nutrient L.B/T.S agar plates using sterilized glass spreader in aseptic conditions. 
The plates were incubated for 12-16 hours followed by counting of viable numbers of 
bacterial colonies. The procedure was performed in triplicate and the average number of 




than 90 percent reduction in number of colonies was considered as MIC concentration. 




XTT assay is a modern, simple, rapid, sensitive, and reliable colorimetric method 
used in cell proliferation, cytotoxicity and apoptosis studies.66 XTT, a yellow 
tetrazolium salt in the presence of a dehydrogenase enzyme in metabolically active cells 
is reduced to bright orange formazan derivative.66 Live cells have reducing environment 
due to electron transport chain mechanism (Figure 3). It measures the viable cell count 
by measuring the reducing activity of cells. Optimum cell concentration and incubation 
time were used based on the best suited culture conditions as observed in growth assays. 
The amount of the formazan produced is proportional to viable cells present and was 
quantified by measuring the absorbance at 492 nm using H1 Synergy plate reader. 
To amplify the results of XTT, an activator called menadione was added.66 50 µL 
of XTT tetrazolium salt stock solution containing menadione (995 µL XTT solution + 5 
µL menadione) was added to the growth curve assay wells (test samples, positive and 
negative control) and plate was incubated for 2 hours at 37 °C, 150 rpm in the dark, 
followed by their absorbance measurement (at 0 and 2 hrs interval of adding XTT) at 
492 nm. A graph of absorbance @ 492 nm against concentration of Kan-GNPs was 




90 % reduction in absorbance as compared to the positive control was taken as the MIC. 









Figure 3. Illustrates bacterial cell viability detection mechanism by XTT assay. 
Metabolically active bacteria due to dehydrogenase enzyme reduces yellow tetrazolium 




Antibacterial assay against kanamycin resistant and MDR bacteria 
For Kan resistant bacteria the minimum inhibitory concentration (MIC) was 
determined. Briefly, for Yersinia pestis 2-fold serially diluted Kan-GNPs concentrations 
were added to wells of a clear microtiter plate. 3x105 colony forming units (CFU) were 
then added and microtiter plates were incubated at 26 °C for 10 hours. Similar microtiter 
plates were prepared for P. aeruginosa, and incubated at 37 °C for 10 hours 
respectively. MICs were determined as Kan-GNPs concentration that completely 
inhibited bacterial growth (MIC100). The average MIC100 from three independent 
experiments was calculated. 
2.6.5. Visualization of bactericidal action of Kan-GNPs 
 Cellular imaging using propidium iodide (PI) was done to determine the 
antibacterial mechanism of Kan-GNPs.67 PI is a red-fluorescent dye which has high 
affinity towards bacterial DNA. Due to its inability to permeate living cells, it can be 
used to detect dead cells in a bacterial population.67 A respective bacterial strain was 
incubated in the presence of the MIC of Kan-GNPs for ~12 hours followed by which the 
samples were repeatedly washed with phosphate buffer saline (PBS) and centrifuged 
(6000 rpm, 3 min). Samples were further incubated with 5 µL of PI (10 mM) for 30 
minutes in the dark. After incubation, unbound PI was removed by washing the sample 
with 1X PBS and 10 µL of the resulting suspension was placed on a glass slide and 
covered with a cover slip. The sample was viewed using a Leica fluorescence 
microscope. A sample of bacteria without Kan-GNPs was taken as control. The numbers 




three individual measurements and a graph was plotted in comparison to control for 
respective bacterial strains. 
 To visualize the morphological changes in bacteria after treating with Kan-
GNPs, cross-sections of bacteria were prepared with the aid of ultramicrotome and 
observed under an transmission electron microscope (TEM).68,69 1 mL of sample 
containing bacterial culture incubated (37 °C, 150 rpm, and 12 hours) in the presence of 
MIC concentration of Kan-GNPs was centrifuged (4000 rpm, 3 min) and the pellet was 
re-suspended in 1 mL of primary fixing solvent (16 % w/v paraformaldehyde and 10 % 
w/v glutaraldehyde in 50 mM sodium cacodylate buffer (pH ~7.4)) and incubated for 2 
hours. After incubation, the solution was centrifuged, washed twice with cacodylate 
buffer, re-suspended in 1 mL of 1% osmium tetroxide solution (OsO4), and further 
incubated for 1 hour at 25 °C for post-fixation. After fixation, the bacterial samples were 
washed using sterile nanopure water. Samples were further treated with series of ethanol 
concentrations (25, 50, 75, 95 and 100 % respectively). The samples were dehydrated 
and further centrifuged. Spur’s epoxy resin in series of (33, 66, 95 and 100 %) was used 
to infiltrate pellets for one hour. The samples were left in contact with 100 % resin 
overnight. The samples were then centrifuged in BEEM® capsules, which were 
solidified by heating at 70 °C for 18 hours. Using glass knives for RMC MT-X ultra-
microtome, ultra-thin sections of sample were cut and stained with 2 % aqueous uranyl 
acetate for 15 minutes and Reynold’s lead citrate for 3 minutes. The samples were then 





3. RESULTS AND DISCUSSION 
3.1.  Synthesis and characterization of Kan-GNPs 
 One of the vital steps in the preparation of GNPs is the addition of chemical 
agents to reduce the ionic gold atoms [Au3+] to neutral gold atoms [Au0] which tends to 
result in aggregation upon reaching the saturation limit. Secondary capping agents are 
further added to stabilize and restrict the size of gold aggregates into the nano-range 
yielding gold nanoparticles. However, using such methods requires the need of multiple 
steps to purify the product from unwanted components, thus making the overall process 
highly expensive and labor intensive which limits scalability. Furthermore, due to the 
biological concerns of the chemical agents used in the synthesis process, emphasis to 
find biologically friendly methods for synthesizing GNPs is growing.  
 In this context, we developed a simple single step method for making antibiotic 
functionalized GNPs. The aminoglycoside kanamycin has electron rich hydroxyl and 
amine functional groups which could serve as a dual reducing and capping agent. Hence, 
kanamycin antibiotic was selected as a proof of concept to synthesize antibiotic capped 
GNPs. The optimum concentration of kanamycin and gold required for GNPs synthesis 
was determined by assessing varying concentrations of both kanamycin and KAuCl4 at 
different synthesis parameters. Based on these analyses, it was determined that 1.72 mM 
of kanamycin in aqueous buffer (pH ~7.2 ± 0.2) when incubated with 0.79 mM of 
KAuCl4 for 5 minutes yielded the optimal production of Kan-GNPs. The kanamycin 





Qualitative analysis of aggregation and morphological characteristics of Kan-
GNPs was obtained under TEM at 100 kV showed the particles to be nearly spherical in 
shape and monodispersed with an average diameter of 20 ± 5 nm (Figure 4(a)). DLS is 
another widely used characterization technique for nanoparticles. DLS analysis of Kan-
GNPs showed a sharp peak with an average size distribution of 20 ± 5 nm (Figure 4(b)) 
which is in agreement with TEM. A UV-Vis spectrum of Kan-GNPs recorded in the 
visible region (400-850 nm) showed a peak absorption (λmax) value at 546 nm (Figure 
4(c)) which is in compliance with the size of GNPs obtained from TEM. 
Scannning electron microscopy coupled with energy dispersive spectroscopy was 
used further to determine the surface elemental composition of Kan-GNPs. Dense 
portions of the highly magnified SEM image of Kan-GNPs were selected where the 
electron beam was focused to obtain the localized elemental (atoms) composition using 
IXRF software. Multiple spots were selected for the analysis. Results of EDS spectral 
analysis revealed the presence of elemental peaks of carbon (C) and gold (Au) at ~0.2 
keV and ~2.1 keV respectively (Figure 4(d)). The percent composition of carbon and 
gold was found to be 16.65 % and 66.55 %, respectively. The presence of a reduced gold 
peak ensured the formation of GNPs whereas the carbon peak confirmed the presence of 
the organic ligand (kanamycin) on the surface of GNPs.  
Thermo gravimetric analysis of Kan-GNPs was used to quantify the amount of 
organic ligand (kanamycin) bound to the surface of GNPs as well as its precent weight 
which is essential in calculating the actual dose of drug for in-vivo studies. Method I 




temperature to 650 °C followed by air till 850 °C whereas, in method II (Appendix: C) 
air was used as purge gas throughout thermal degradation in order to facilitate complete 
oxidation. The weight loss for Kan-GNPs was observed to be 35 % of the total mass 
(Figure 4(e)). TGA of pure kanamycin was also performed for reference as shown in 
(Figure 4(e)). Zeta potential was used to determine surface charge of Kan-GNPs. Kan-








Figure 4. Illustration of the morphological characterization of Kan-GNPs. (a) TEM 
image showing formation of well-dispersed nearly spherical Kan-GNPs in the size range 
of 20 ± 5 nm. (b) Plot showing average particle size distribution of Kan-GNPs 
suspension obtained using DLS. (c) UV-Vis spectra of Kan-GNPs showing a strong 
absorption peak at 546 nm which is a characteristic of spherical GNPs. (d) Energy 
dispersive spectroscopy (EDS) spectra of Kan-GNPs showing the presence of elemental 
peak for carbon (C) and gold (Au) at 0.2 keV and 2.1 keV, respectively. Figure in the 
inset shows SEM image of spin coated sample of Kan-GNPs on silicon chip obtained at 
an accelerating voltage of 20 keV with a magnification of 5kX. (e) A comparison of 
thermo gravimetric (TGA) analysis showing loss of organic material for kanamycin (----
) and Kan-GNPs (- - -) respectively. The samples were heated from room temperature to 






3.2.  Kan-GNPs have antibacterial activity 
We evaluated the antibacterial efficacy of Kan-GNPs against a variety of Gram-
positive (Staphylococcus epidermidis and Enterococcus durans) and Gram-negative 
(Escherichia coli and Enterobacter aerogenes) bacterial strains by observing the 
bacterial growth in the presence of different concentrations of Kan-GNPs. The MIC was 
determined as the lowest concentration of Kan-GNPs which showed complete inhibition 
of bacterial growth or at least 90 % reduction in the absorbance of growth at 600 nm 
when compared to untreated bacteria. 
Overnight culture of each bacterial strain was incubated (37 °C, 150 rpm) with 
different concentrations of Kan-GNPs and their growth was observed for a period of 12 
hours in a 96-well microtiter plate. To verify the broad-spectrum activity of Kan-GNPs, 
antibacterial tests were performed on both Gram-positive and Gram-negative strains. A 
graph was plotted for O.D600 nm against time (hrs). In general, dose-dependent inhibition 
of bacterial growth was observed for all bacterial strains. From the above assay MIC of 
24.46 µg mL-1 and 35.23 µg mL-1 (Kan-GNPs) was observed against Gram-positive 
strains S. epidermidis and E. durans respectively (Table 6). Results for the Gram-
negative strains E. aerogenes and E. coli were found to be 21.82 µg mL-1 and 25.06 µg 
mL-1, respectively. The MIC value observed in the bacterial growth assay was consistent 
with the spread plate assay as no visible growth of bacterial colonies were observed in 













Figure 5. Illustrates dose dependent inhibition of bacterial growth by Kan-GNPs against 
Gram positive, S. epidermidis (a, b) and Gram negative E. aerogenes (c, d) bacteria. (a 
and c) Monitoring growth in the presence of increasing concentration of Kan-GNPs by 
measuring the OD at 600 nm every 3 hours for a period of 12 hours. MIC of Kan-GNPs 
was found to be 24.46 µg/mL and 21.82 µg/mL against S. epidermidis and E. aerogenes 
bacteria, respectively. (b and d) Visualizing the growth of S. epidermidis and E. 
aerogenes bacteria on a solid agar plate in presence of MIC of Kan-GNPs obtained from 




To check the precision of the results, XTT, a cell viability assay was performed. 
Viable or metabolically active cells have potential to convert the water-soluble XTT to a 
water-soluble, orange colored formazan product which can be easily quantified 
colorimetrically. The lowest concentration in the well which showed no orange color 
formation or 90 % reduction in the absorption at 492 nm (characteristic for XTT) was 
taken as the MIC. The MIC values of XTT assay for Gram-positive strain S. epidermidis 
(Figure 6 (a and b)) and Gram-negative strain E. aerogenes (Figure 6 (c and d)) were in 
compliance with the previous assays. 
A comparison of results showed approximately two fold reduction in the MIC of 
Kan-GNPs for all the bacterial strains tested when compared to the pure kanamycin 
(Table 6). Therefore, kanamycin conjugated on to GNPs surface is more efficient in 
















Figure 6. Colorimetric illustration of dose dependent inhibition by Kan-GNPs against 
Gram-positive, S. epidermidis (a, b) and Gram-negative E. aerogenes (c, d) bacteria. (a 
and c) Susceptibility testing against varying concentrations of Kan-GNPs by 
colorimetric assay which involves reduction of a yellow tetrazolium salt (XTT) to 
orange formazan product by metabolic active bacterial cells. The MICs were similar to 
the MIC obtained using growth assay and spread plate. (b and d) A plot corresponding to 
XTT assay obtained by measuring absorbance of wells at 492 nm, which shows peak 
absorption for orange formazan derivative. Wells with 90 % reduction in absorbance 






Table 6. MIC100 of Kan and Kan-GNPs (µg/mL) 
  Kan Kan-GNPs Fold Change 
Gram Positive 
S. epidermidis 40 24.46 1.64 
E. durans 100 35.23 2.85 
Gram Negative 
E. coli 60 25.06 2.39 
E. aerogenes 40 21.82 1.83 
Table 6. Illustration of MIC of Kan-GNPs against Gram-positive and Gram-negative 
strains in comparison to pure kanamycin. The growth in presence of increasing 
concentrations of Kan-GNPs was monitored by measuring the optical density (O.D) at 
600 nm every 3 hours for a period of 12 hours to determine the MIC. Decrease in the 
MIC of Kan-GNPs compared to pure kanamycin proved Kan-GNPs enhanced potential 

















Next we tested whether Kan-GNPs have greater efficacy than kanamycin against 
kanamycin resistant and MDR bacteria. Two kanamycin resistant bacterial strains were 
used, a genetically engineered Y. pestis kanamycin resistant strain (CO92::Km) and a 
multidrug resistant P. aeruginosa clinical isolate (UNC-D). The MIC100 of kanamycin 
against both of these strains is significantly higher than equivalent kanamycin sensitive 
strains (WT Y. pestis CO92 and P. aeruginosa PA01; Table 7). When kanamycin 
sensitive bacteria were incubated with Kan-GNPs a 2.88- and 7.50-fold decrease in 
kanamycin concentration was required when bound to GNPs to inhibit the growth of Y. 
pestis CO92 and P. aeruginosa PA01 respectively. In the case of the kanamycin 
resistant and MDR bacterial strains, we observed even higher impact of GNPs on the 
kanamycin MICs, with a 13.50- and 41.88-fold decrease in MICs for Y. pestis 
CO92::Km and P. aeruginosa UNC-D, respectively. Importantly, GNPs linkage to 
kanamycin resulted in kanamycin MICs similar to the kanamycin alone MICs of the 
kanamycin sensitive strains. Taken together, our data demonstrate that GNPs linkage to 













Table 7. MIC100 of Kan and Kan-GNPs (µg/mLa) 
  Kan Kan-GNPs Fold Change 
P. aeruginosa 
PA01 50 6.67 7.5 
UNC D-1 (MDRb) 139.46 3.33 41.88 
Y. pestis 
CO92 4.81 1.67 2.88 
CO92::Km 180 13.33 13.5 
aConcentration of Kan 
bMultidrug resistant 
Table 7. Illustration of MIC of Kan-GNPs against genetically engineered Y. pestis 
kanamycin resistant strain (CO92::Km) and a multidrug resistant P. aeruginosa clinical 
isolate (UNC-D). The growth in presence of increasing concentrations of Kan-GNPs 
was monitored by measuring the optical density (OD) at 600 nm every 3 hours for a 
period of 12 hours to determine the MIC. The MIC100 of kanamycin against both of 
these strains is significantly higher than equivalent kanamycin sensitive strains (WT Y. 
pestis CO92 and P. aeruginosa PA01; Table 7). When kanamycin sensitive bacteria 
were incubated with Kan-GNPs a 2.88- and 7.50-fold decrease in kanamycin 
concentration was required when bound to GNPs to inhibit the growth of Y. pestis CO92 
and P. aeruginosa PA01, respectively. For kanamycin resistant strains, a higher impact 
of GNPs on the kanamycin MICs, with a 13.50- and 41.88-fold decrease in MICs for Y. 











3.3.  Kan-GNPs treatment alters the morphology of bacteria 
The morphology of Gram-positive (S. epidermidis) and Gram-negative (E. 
aerogenes) bacteria against Kan-GNPs was determined by examining ultra-thin sections 
of the samples under electron microscope (TEM), obtained using an ultra-microtome, 
collected at various time intervals (0, 6 and 12 hours) of bacterial growth. A series of 
morphological changes were observed for bacterial cells treated with nanoparticles. 
Based on TEM observation, after 6 hours of incubation, Kan-GNPs were found to be 
localized on the cell membrane, covering most of the surface of Gram-positive S. 
epidermidis bacteria. Nanoparticles were also observed in the cytoplasm which shows 
the ability of Kan-GNPs to permeate the bacterial cell wall. As a result of perforations 
into the cell wall, disruption and leakage of cytoplasmic contents were observed after 12 
hours resulting in complete cell lysis (Figure 7(a)). Cross-sectional TEM images showed 
localization of Kan-GNPs on the surface as well as entry into the cytoplasm, suggesting 
bactericidal action of Kan-GNPs resulting in the dual killing effect. A similar pattern of 
lysis of bacterial cell wall by Kan-GNPs was observed against Gram-negative E. 

















Figure 7. TEM images for visualizing the morphological changes in bacteria upon 
treating with Kan-GNPs at different intervals of time. Panel (a) represents sequential 
images (from left to right) of Gram positive, S. epidermidis bacteria treated with Kan-
GNPs (24.46 µg mL-1) after 0 hour, 6 hours and 12 hours of incubation. Panel (b) 
Represents sequential images (from left to right) of Gram negative, E. aerogenes 
bacteria treated with Kan-GNPs (21.82 µg mL-1) after 0 hour, 6 hours and 12 hours of 
incubation. After 6 hours of exposure, Kan-GNPs were found to adhere and penetrate 
the bacterial cell wall which resulted in disruption of cellular environment leading to 





Permeability of Kan-GNPs into the bacterial cytoplasm is crucial for the delivery 
of attached kanamycin to inhibit the bacterial protein synthesis. To assess the 
permeability of Kan-GNPs, fluorescence imaging using propidium iodide (PI) was used. 
PI dye which shows fluorescence after binding to nucleic acids in membrane 
compromised cells, was used to detect dead cells. Kan-GNPs treated samples of S. 
epidermidis (24.46 µg mL-1) and E. aerogenes (21.82 µg mL-1), after incubating for 12 
hours at 37 °C were stained with PI dye followed by further incubation in the dark for 2 
hours (Figure 8(a)). Fluorescence images of the samples showed 75 ± 10% permeability 
of Kan-GNPs for S. epidermidis and E. aerogenes respectively when compared to 
control which showed only 15 ± 10% permeability for S. epidermidis and E. aerogenes 
























Figure 8. Fluorescence images of Kan-GNPs induced cell membrane permeability using 
propidium iodide (PI) dye which has strong binding affinity towards nucleic acids. 
Upper panel represents Gram-positive, S. epidermidis and lower panel represents Gram-
negative, E. aerogenes. (a) The image represents differential interference contrast mode 
with corresponding fluorescence image. Untreated samples of respective bacteria 
without Kan-GNPs were taken as control. (b) Represents a plot showing percentage 
permeability of S. epidermidis and E. aerogenes bacterial cells in presence (MIC) and 




These results supported the observation from TEM cross-section images 
confirming bactericidal action of Kan-GNPs resulting in lysis of bacterial cell. Kan-
GNPs binds to the surface of the bacterial cell wall, making perforations which disrupts 
cellular equilibrium. In addition, free kanamycin existing on GNPs surface may also 
bind to the 30S ribosome and inhibit protein synthesis, thereby retaining its inherent 
pharmacological activity.70 We also hypothesize that due to the presence of amine 
groups in kanamycin, which can easily be protonated (RNH2 + H2O  RNH3
+) 
imparting a partial positive charge to the Kan-GNPs, could bind to the negatively 
charged DNA (due to presence of phosphate) and unwind the two strands, resulting in 
disruption in DNA.62 The positive amine groups could also facilitate in binding with the 
negatively charged bacterial cell wall as observed from the TEM pictures.71,72 
Correlating the hypothetical antibacterial mechanism of Au@TiO2 systems,
73 Kan-GNPs 
present on the surface of bacteria could also extract electrons from the bacterial 
respiratory proteins, thereby starving bacteria to death. In addition, the internalized Kan-
GNPs could affect important biological processes in bacteria such as ATP synthesis, 
protein synthesis and many more.74 As a result of multiple routes of bactericidal action, 
it becomes relatively problematic for the bacteria to resist the action of antibiotic GNPs, 
thereby making them more favorable for clinical use as an effective antibacterial agent. 
One of the major concerns regarding the use of GNPs for clinical applications is its 
cytotoxicity which is still under debate. In a previous study, spherical gold nanoparticles 








 Our results illustrates a novel and efficient antibacterial strategy involving the 
use of a commercial antibiotic, kanamycin capped onto the surface of gold nanoparticles 
through a single-step process without the use of any toxic chemicals. Monodisperse, 
spherical GNPs in the size range of 20 ± 5 nm were formulated which showed dose-
dependent bactericidal activity against both Gram-positive and Gram-negative bacteria. 
Significant decrease in the MIC of Kan-GNPs in comparison to pure kanamycin proved 
Kan-GNPs enhanced potential in combating Kan-resistant and MDR bacteria. Kan-
GNPs were found to kill bacteria by causing perforations in the bacterial cell wall, as 
well as probably due to the protein inhibition activity of free kanamycin on the surface, 
causing loss of cellular integrity leading to leakage of cell constituents, which eventually 
resulted in lysis of the bacterial cell. In conclusion, we report a simple, bio-friendly 
process using combined reducing and capping ability of kanamycin to produce stable 
and efficient GNPs which holds a promising future for its clinical use as a potent 
antibacterial agent against multi drug resistant bacteria. This could facilitate biomedical 
application of Kan-GNPs and can open a new route for other commercially available 













5. FUTURE STUDIES 
 
In vivo interation of Kan-GNPs in animal model 
In order to use a nanoformulation for biological applications, the Kan-GNPs 
should be tested for in vivo activity in experimental animal models. This will be done by 
studying the physiological changes occuring in animal system upon acute and chronic 
exposure to Kan-GNPs.76 The MIC concentration of Kan-GNPs will be administered 
intravenously to the experimental animal model and animals will be studied for various 
parameters such as change in body temperature, body weight and behaviour before and 
after treatment with Kan-GNPs.76 The blood and urine samples will be collected at 
specific time intervals and tested for hematological and urinary analysis. For detailed 
interaction studies, serum biochemical and histo-pathological analysis will also be 
done.76 All the toxicity analysis will be done for Kan-GNPs and will be compared with 
pure kanamycin. 
Pharmacokinetic (PK) and pharmacodynamic (PD) studies of Kan-GNPs 
After succesful quantitative analysis of Kan-GNPs for in vivo applications, we 
will study the the Absorption Distribution Metabolism Excretion (ADME) profile of 
kanamycin nanoformulation which will give us pharmacokinetic information, whereas 
efficacy and toxicity studies in pre-clinical models will provide us pharmacodynamic 
information of Kan-GNPs.77 The ADME, PK and PD studies of Kan-GNPs will be done 
by collecting samples from blood, tissues, plasma, bile and urine upon treating animal 
model with Kan-GNPs and will be tested for drug concentration, half life, clearance, 
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7.1. Appendix A: Product specification of kanamycin sulfate, Streptomyces 
kanamyceticus 
 
Product Name: Kanamycin sulfate, Streptomyces kanamyceticus 
Chemical Formula: C18H36N4O11. H2SO4 
Formula Weight: 582.6 g/mole 
Description: White odorless crystalline powder 
Solubility: Soluble in water (10 mg/mL) 
Turbidity: Clear 
Storage: 15 – 30 °C 
Supplier: EMD Millipore 
Specifications: Contains more than 98 % kanamycin  
Figure 9. Illustrates structure of kanamycin sulfate. a) Represents chemical structure 
of kanamycin sulfate. b) Represents molecular model of kanamycin sulfate 




7.2. Appendix B: Thermo gravimetric analysis protocols of Kan-GNPs 
 



























Figure 10. Represents method for thermal degradation of Kan-

































Figure 11. Represents method for thermal degradation of Kan-GNPs in 
presence of air as purge gas. In this method, air was selected as purge gas 
for complete sample run in order to determine percent weight loss of Kan-

































Figure 12. Represents thermal degradation plot showing weight loss of organic 
material for kanamycin (----) and Kan-GNPs (- - -) respectively using air as 
purge gas. The samples were heated from room temperature till 850 °C using 
air as purge gas in order to facilitate complete oxidation of organic compound. 
Kan-GNPs showed weight loss of 35.05 % which is comparable to percent 





















Figure 13. Represents design of 96 wells microtiter plate. All sample reactions were 
done in triplicate. Sample row contained varying concentration of Kan-GNPs 
concentrated to 100 µL as final volume, 140 µL nutrient media and 10 µL of bacterial 
culture (1 x 106 CFU per mL). Blank wells contains same concentrations of drug as in 
sample rows and 150 µL nutrient media. Control wells contained 100 µL sterilized 
nanopure water, 140 µL nutrient media and 10 µL of bacterial culture. For XTT assay, 
50 µL of XTT solution (previously activated with menadione) was added to each 
sample, blank and control wells. 
